title: The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers.
abstract: The rise in genomic knowledge over the past decade has revealed the molecular etiology of many diseases, and has identified intricate signaling network activity in human cancers. Genomics provides the opportunity to determine genome structure and capture the activity of thousands of molecular events concurrently, which is important for deciphering highly complex genetic diseases such as cancer. In this review, we focus on genomic efforts directed towards one of cancer's most frequently mutated networks, the RAS pathway. Genomic tools such as gene expression signatures and assessment of mutations across the RAS network enable the capture of RAS signaling complexity. Due to this high level of interaction and cross-talk within the network, efforts to target RAS signaling in the clinic have generally failed, and we currently lack the ability to directly inhibit the RAS protein with high efficacy. We propose that the use of gene expression data can identify effective treatments that broadly inhibit the RAS network as this approach measures pathway activity independent of mutation status or any single mechanism of activation. Here, we review the genomic studies that map the complexity of the RAS network in cancer, and that show how genomic measurements of RAS pathway activation can identify effective RAS inhibition strategies. We also address the challenges and future directions for treating RAS-driven tumors. In summary, genomic assessment of RAS signaling provides a level of complexity necessary to accurately map the network that matches the intricacy of RAS pathway interactions in cancer.
authors.affiliation: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA.
authors.forename: Gajendra
authors.initials: G
authors.lastname: Shrestha
authors.affiliation: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA; Department of Oncological Sciences, University of Utah, Salt Lake City, UT, USA.
authors.forename: Shelley M
authors.initials: SM
authors.lastname: MacNeil
authors.affiliation: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA; Department of Oncological Sciences, University of Utah, Salt Lake City, UT, USA.
authors.forename: Jasmine A
authors.initials: JA
authors.lastname: McQuerry
authors.affiliation: Division of Computational Biomedicine, Boston University School of Medicine, Boston, MA, USA.
authors.forename: David F
authors.initials: DF
authors.lastname: Jenkins
authors.affiliation: Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA; Center for Investigational Therapeutics, Huntsman Cancer Institute, Salt Lake City, UT, USA.
authors.forename: Sunil
authors.initials: S
authors.lastname: Sharma
authors.affiliation: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA; Department of Oncological Sciences, University of Utah, Salt Lake City, UT, USA. Electronic address: andreab@genetics.utah.edu.
authors.forename: Andrea H
authors.initials: AH
authors.lastname: Bild
mesh_terms: D000818:Animals; D023281:Genomics; D006801:Humans; D008954:Models, Biological; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D015398:Signal Transduction; D018631:ras Proteins / Q000378:metabolism*
chemical_list: D018631:ras Proteins
keywords: Cancer; Gene expression signature; Genomics; RAS; Targeted therapy